Cancer: Phosphodiesterase type 4C (PDE4C), the forgotten subfamily as a therapeutic target.

Int J Biochem Cell Biol

School of Cardiovascular and Metabolic Health, College of Veterinary Medical and Life Science, University of Glasgow, Glasgow, UK. Electronic address:

Published: September 2023

Phosphodiesterase type 4 (PDE4) enzymes specifically hydrolyse cAMP in many cell signalling systems that are transduced by hormones and other primary messengers. The physiological function of the four PDE4 subfamilies (A, B, C and D) are numerous and varied due to the differentially localised plethora of isoforms that can be detected in cardiovascular, CNS and immune systems. Of the four subfamilies, least is known about PDE4C probably due to its restricted distribution pattern, scarcity of selective inhibitors and the lack of developed research tools. Here, for the first time, we chart the discovery of PDE4C, describe its regulation and highlight cancers where future development of PDE4C selective small molecules may have potential.

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.biocel.2023.106453DOI Listing

Publication Analysis

Top Keywords

phosphodiesterase type
8
cancer phosphodiesterase
4
pde4c
4
type pde4c
4
pde4c forgotten
4
forgotten subfamily
4
subfamily therapeutic
4
therapeutic target
4
target phosphodiesterase
4
type pde4
4

Similar Publications

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!